211 related articles for article (PubMed ID: 37303034)
1. The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.
Karlsson WK; Ashina H; Cullum CK; Christensen RH; Al-Khazali HM; Amin FM; Ashina M;
J Headache Pain; 2023 Jun; 24(1):70. PubMed ID: 37303034
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.
Al-Khazali HM; Ashina H; Christensen RH; Wiggers A; Rose K; Iljazi A; Amin FM; Ashina M; Snellman J; Maio-Twofoot T; Schytz HW
Cephalalgia; 2024 Jun; 44(6):3331024241258734. PubMed ID: 38859744
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
4. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
5. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab.
Schwedt TJ; Nikolova S; Dumkrieger G; Li J; Wu T; Chong CD
J Headache Pain; 2022 Dec; 23(1):159. PubMed ID: 36517767
[TBL] [Abstract][Full Text] [Related]
7. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
8. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
9. An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study.
Al-Khazali HM; Ashina H; Christensen RH; Wiggers A; Rose K; Iljazi A; Schytz HW; Amin FM; Ashina M
Cephalalgia; 2023 Oct; 43(10):3331024231206375. PubMed ID: 37815254
[TBL] [Abstract][Full Text] [Related]
10. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials.
Christensen CE; Younis S; Deen M; Khan S; Ghanizada H; Ashina M
J Headache Pain; 2018 Nov; 19(1):105. PubMed ID: 30409109
[TBL] [Abstract][Full Text] [Related]
11. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
[TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
[TBL] [Abstract][Full Text] [Related]
13. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.
Belvís R; Irimia P; Pozo-Rosich P; González-Oria C; Cano A; Viguera J; Sánchez B; Molina F; Beltrán I; Oterino A; Cuadrado E; Gómez-Camello A; Alberte-Woodward M; Jurado C; Oms T; Ezpeleta D; de Terán JD; Morollón N; Latorre G; Torres-Ferrús M; Alpuente A; Lamas R; Toledano C; Leira R; Santos S; Del Río MS
J Headache Pain; 2021 Jul; 22(1):74. PubMed ID: 34273947
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ
J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
[TBL] [Abstract][Full Text] [Related]
17. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
19. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
20. The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.
Schwedt TJ; Digre K; Tepper SJ; Spare NM; Ailani J; Birlea M; Burish M; Mechtler L; Gottschalk C; Quinn AM; McGillicuddy L; Bance L; Dumkrieger G; Chong CD; Dodick DW
Headache; 2020 Feb; 60(2):337-347. PubMed ID: 31755111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
